This study will be a randomized, double-blind, placebo-controlled, multicenter trial
conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with
discontinuing cannabis in participants with moderate to severe Cannabis Use Disorder (CUD).
The study will enroll approximately 225 participants with moderate to severe CUD and will
include 5 arms, including a placebo arm, to help assess the incidence and severity of
withdrawal symptoms in heavy long-term users of cannabis. Participants receive study
medication for 34 days and participate in 11 visits (7 at a clinic and 4 telemedicine).